Szarek, Michael

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 3,634

Sotagliflozin in patients with diabetes and recent worsening heart failure

Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 1,868

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 1,610

Sotagliflozin in patients with diabetes and chronic kidney disease

Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,205

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

Bittner, V. A., Szarek, M., Aylward, P. E., Bhatt, D. L., Diaz, R., Edelberg, J. M., Fras, Z., Goodman, S. G., Halvorsen, S., Hanotin, C., et al. (2020) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 572

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment

Kastelein, J. J. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., et al. (2008) · Circulation

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 478

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

Tavazoie, M. F., Pollack, I., Tanqueco, R., Ostendorf, B. N., Reis, B. S., Gonsalves, F. C., Kurth, I., Andreu-Agullo, C., Derbyshire, M. L., Posada, J., et al. (2018) · Cell

Immune cells in cancerCancer Immunotherapy and Biomarkers

Cited by 476

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

Schwartz, G. G., Bessac, L., Berdan, L. G., Bhatt, D. L., Bittner, V., Diaz, R., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., et al. (2014) · American Heart Journal

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 408

Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome

Jukema, J. W., Szarek, M., Zijlstra, L. E., de Silva, H. A., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., et al. (2019) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 243

High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial

Tsimikas, S., Witztum, J. L., Miller, E. R., Sasiela, W. J., Szarek, M., Olsson, A. G., & Schwartz, G. G. (2004) · Circulation

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 225

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events

Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., Chiang, C.-E., Diaz, R., Edelberg, J. M., Goodman, S. G., et al. (2019) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 173

Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial

Bhatt, D. L., Eikelboom, J. W., Connolly, S. J., Steg, P. G., Anand, S. S., Verma, S., Branch, K. R. H., Probstfield, J., Bosch, J., Shestakovska, O., et al. (2020) · Circulation

Antiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease Management

Cited by 158

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)

Charlton-Menys, V., Betteridge, D. J., Colhoun, H., Fuller, J., France, M., Hitman, G. A., Livingstone, S. J., Neil, H. A. W., Newman, C. B., Szarek, M., et al. (2009) · Clinical Chemistry

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 94

Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial

Goodman, S. G., Steg, P. G., Poulouin, Y., Bhatt, D. L., Bittner, V. A., Diaz, R., Garon, G., Harrington, R. A., Jukema, J. W., Manvelian, G., et al. (2023) · Journal of the American Heart Association

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 44

Early, intensive statin treatment reduces ‘hard’ cardiovascular outcomes after acute coronary syndrome

Schwartz, G. G., Fayyad, R., Szarek, M., DeMicco, D., & Olsson, A. G. (2017) · European Journal of Preventive Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 44

Alirocumab after acute coronary syndrome in patients with a history of heart failure

White, H. D., Schwartz, G. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Chiang, C.-E., Diaz, R., Goodman, S. G., Jukema, J. W., Loy, M., et al. (2022) · European Heart Journal

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 41

Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT

Szarek, M., Bhatt, D., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Tardif, J. C., Ballantyne, C. M., Ketchum, S. B., Pineda, A. L., et al. (2023) · European Heart Journal

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 9